Published on May 18, 2010 at 4:49 AM
Actelion Ltd (SIX: ATLN) announced today that findings from the REVEAL® (Registry to EValuate Early And Long-term PAH Disease Management) Registry have confirmed the clinical utility of the REVEAL risk score calculator, a new tool designed to predict 1-year survival in patients with pulmonary arterial hypertension (PAH) according to data presented at the American Thoracic Society's (ATS) Annual International Conference. The predictive tool was developed and validated in patients enrolled in REVEAL, the largest prospective registry in PAH containing data from more than 3,500 patients.
"The REVEAL risk score calculator provides an innovative approach to better understand pulmonary arterial hypertension by looking at a unique combination of variables, that together, can help predict patient survival," said Raymond L. Benza, M.D., Medical Director of the Gerald McGinnis Cardiovascular of Advanced Heart Failure, Transplantation, Mechanical Circulatory Support and Pulmonary Hypertension Program, and Director of the Gerald McGinnis Cardiovascular Institute Center for Research and Innovation at Allegheny General Hospital, Pittsburgh. "We look forward to obtaining more data from the REVEAL Registry that can be used as an adjunct to the clinical experience and judgment of physicians who treat this chronic and life-threatening disease."
SOURCE Actelion Ltd
95808758-c11a-4534-af10-c3adedfb7494|0|.0
Posted in: Device / Technology News | Medical Condition News
Tags: Blood Pressure, Blood Vessel, Endothelin, Exercise, Heart Failure, HIV/AIDS, Hospital, Life Expectancy, Lupus, Nitric Oxide, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Scleroderma